ClinicalTrials.gg
RecruitingNCT07133308Updated Jan 28, 2026

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

A Phase 3 interventional study of Deuruxolitinib and Placebo in Alopecia Areata, sponsored by Sun Pharmaceutical Industries, Inc.. Recruiting at 64 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Sun Pharmaceutical Industries, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Planned enrollment
5th of 10
355 · median 336
Started
2025
the only one that year
Phase 3
5 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Sun Pharmaceutical Industries, Inc.

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 3, and was the 9th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

Read the detailed description

The efficacy and safety of deuruxolitinib in adolescent subjects with severe alopecia areata will be evaluated in this study, beginning with a double-blind, randomized, placebo-controlled Treatment Period of 24 weeks. Subjects 12 to \<18 years of age having at least 50% hair loss as measured by SALT and meeting eligibility criteria will be randomized to deuruxolitinib or placebo treatment. In the Open-label Extension part of the study, participants from the Treatment Period will receive deuruxolitinib for 52 weeks.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.
  • Between 12 to \<18 years of age
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.
  • Willing to comply with the study visits and requirements of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline
  • Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
  • medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
355 participants (estimated)

Study arms

  • Experimental
    Treatment Period: Deuruxolitinib 8 mg

    Deuruxolitinib tablets, orally, twice daily (BID) for up to 24 weeks

    Drug: Deuruxolitinib

  • Placebo comparator
    Treatment Period: Placebo

    Deuruxolitinib-matched placebo tablets, orally, BID for up to 24 weeks

    Drug: Placebo

  • Experimental
    Open-Label Extension: Deuruxolitinib 8 mg BID

    Deuruxolitinib tablets, orally, BID for up to 52 weeks

    Drug: Deuruxolitinib

Interventions

  • Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg

  • DrugPlacebo

    Deuruxolitinib matching placebo will be dosed orally as tablets

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieving an absolute Severity of Alopecia Tool (SALT) score ≤20

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Week 24

  2. Safety and tolerability of deuruxolitinib will be assessed by evaluating adverse events, vital signs, electrocardiograms, and clinical laboratory results, as well as physical examinations

    Summary of participants who experience Treatment emergent adverse events (TEAEs) and serious TEAEs will be provided. An AE is defined as any untoward medical occurrence that may appear or worsen in a subject during the course of a study. Adverse events will be considered treatment-emergent if the onset is after the first dose of study drug. Summaries will be provided of participants who experience potentially clinically significant post-baseline changes in: hematology, chemistry and lipid results, vital signs (blood pressure, pulse rate, respiratory rate, temperature), electrocardiogram parameters (heart rate, PR, QT, QTcF, QRS, and RR) and physical examination findings.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of subjects achieving an absolute SALT score of ≤20

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, and 20

  2. Mean percent change (ie, relative change) in SALT scores from baseline

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  3. Percentage of responders (defined as "much improved" or "very much improved") using the Clinical Global Impression of Improvement (CGI-I)

    The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders will defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  4. Percentage of responders (defined as "much improved" or "very much improved") using the Patient Global Impression of Improvement (PGI-I)

    The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders will be defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  5. Mean change from baseline in the Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Weeks 12, 16, 20, and 24

  6. Mean change from baseline in the Patient Global Impression of Severity (PGI-S)

    The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Weeks 12, 16, 20, and 24

  7. Percentage of subjects achieving an absolute SALT score of ≤10

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  8. Mean change from baseline on the Eyebrow Clinician-Reported Outcome (ClinRO) score

    The Clinician-Reported Outcome Measure of Eyebrow Hair is a clinician-rated scale that assesses the total eyebrow hair present, based on a 4-point scale.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  9. Mean change from baseline on the Eyelash Clinician-Reported Outcome (ClinRO) score

    The Clinician-Reported Outcome Measure of Eyelash Hair is a clinician-rated scale that assesses the total eyelash hair present, based on a 4-point scale

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  10. Percentage of responders (defined as "satisfied" or "very satisfied") on the Satisfaction of Hair Patient Reported Outcome (SPRO) scale

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  11. Mean change from baseline in the SPRO scale

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  12. Percentage of subjects achieving SALT score of ≤ 20 at Week 24 whose SPRO rating shifted from Very Dissatisfied or Dissatisfied to Very Satisfied or Satisfied

    Time frame: Week 24

  13. Percentage of subjects achieving SALT score of ≤ 10 at Week 24 whose SPRO rating shifted from Very dissatisfied or Dissatisfied to Very Satisfied or Satisfied

    Time frame: Week 24

  14. Mean change from baseline on the individual items of the Quality of Hair Patient Reported Outcome (QPRO) scale

    The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24

  15. Mean change from baseline in total score of the Hospital Anxiety and Depression Scale (HADS)

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  16. Mean change from baseline in the depression scale of the HADS

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  17. Mean change from baseline in the anxiety scale of the HADS

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  18. Percentage of subjects achieving a ≥ 6-point change from baseline in total score of the HADS

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  19. Percentage of subjects achieving a ≥ 3-point change from baseline in the depression scale of the HADS

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  20. Percentage of subjects achieving a ≥ 4-point change from baseline in the anxiety scale in total score of the HADS

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Weeks 12 and 24

  21. Proportion of Participants with Suicidal Ideation or Behavior Per the Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a "yes" answer to any of 5 suicidal behavior questions. Suicidal ideation is defined as a "yes" answer to either Questions 4 or 5 on the suicidal ideation section (with intent or plan).

    Time frame: Week 24

  22. Safety and tolerability of deuruxolitinib will be assessed by evaluating adverse events, vital signs, electrocardiograms, and clinical laboratory results, as well as physical examinations

    Summary of participants who experience Treatment emergent adverse events (TEAEs) and serious TEAEs will be provided. An AE is defined as any untoward medical occurrence that may appear or worsen in a subject during the course of a study. Adverse events will be considered treatment-emergent if the onset is after the first dose of study drug. Summaries will be provided of participants who experience potentially clinically significant post-baseline changes in: hematology, chemistry and lipid results, vital signs (blood pressure, pulse rate, respiratory rate, temperature), electrocardiogram parameters (heart rate, PR, QT, QTcF, QRS, and RR) and physical examination findings.

    Time frame: Up to Week 80

  23. Effect of deuruxolitinib on treating Hair Loss as Measured by the Severity of Alopecia Tool (SALT)

    Time frame: Up to Week 76

07

Study locations

64 of 64 sites recruiting
  • Total Skin And Beauty Dermatology Center
    Birmingham, Alabama 35203, United States
    Recruiting
  • Avacare - Cct Research - Center For Dermatology And Plastic Surgery
    Scottsdale, Arizona 85260, United States
    Recruiting
  • Dermatology Trial Associates
    Bryant, Arkansas 72022, United States
    Recruiting
  • Kern Research Inc.
    Bakersfield, California 93301, United States
    Recruiting
  • Center For Dermatology Clinical Research Inc.
    Fremont, California 94538, United States
    Recruiting
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
    Recruiting
  • Palmtree Clinical Research
    Palm Springs, California 92262, United States
    Recruiting
  • Paradigm Clinical Research - San Diego
    San Diego, California 92108, United States
    Recruiting
  • Colorado Medical Research Center
    Denver, Colorado 80210, United States
    Recruiting
  • Paradigm Clinical Research - Wheat Ridge
    Wheat Ridge, Colorado 80033, United States
    Recruiting
  • D&H Doral Research Center
    Doral, Florida 33122, United States
    Recruiting
  • Skin Care Research, Llc - Hollywood
    Hollywood, Florida 33021, United States
    Recruiting
  • Ilumina Medical Research Llc
    Kissimmee, Florida 34744, United States
    Recruiting
  • All X Ray Diagnostic Services Corp
    Miami, Florida 33126, United States
    Recruiting
  • Millennium Medical Research Llc
    Miami, Florida 33126, United States
    Recruiting
  • Florida International Medical Research
    Miami, Florida 33134, United States
    Recruiting
  • Florida Pharmaceutical Research And Associates, Inc.
    Miami, Florida 33143, United States
    Recruiting
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
    Recruiting
  • Pediatric Skin Research Llc
    Miami, Florida 33156, United States
    Recruiting
  • Valencia Medical & Research Center
    Miami, Florida 33174, United States
    Recruiting
  • Advance Research Center, Llc
    Miami, Florida 33183, United States
    Recruiting
  • Barroso Medical Services Llc
    Miami Lakes, Florida 33014, United States
    Recruiting
  • Nexus Research Llc
    Pompano Beach, Florida 33063, United States
    Recruiting
  • International Clinical Research Us Llc - Sanford
    Sanford, Florida 32771, United States
    Recruiting
  • Lenus Research & Medical Group Llc.
    Sweetwater, Florida 33172, United States
    Recruiting
  • Cleaver Medical Group Dermatology
    Cumming, Georgia 30040, United States
    Recruiting
  • Skin Care Physicians Of Georgia
    Macon, Georgia 31217, United States
    Recruiting
  • Georgia Skin & Cancer Clinic
    Savannah, Georgia 31419, United States
    Recruiting
  • Asr, Llc
    Boise, Idaho 83702, United States
    Recruiting
  • Denova Research
    Chicago, Illinois 60611, United States
    Recruiting
  • Ds Research - Indiana
    Clarksville, Indiana 47129, United States
    Recruiting
  • Dawes Fretzin Clinical Research Group Llc.
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Ds Research - Kentucky
    Louisville, Kentucky 40241, United States
    Recruiting
  • U.S. Dermatology Partners - Rockville
    Rockville, Maryland 20850, United States
    Recruiting
  • Oakland Hills Dermatology
    Auburn Hills, Michigan 48326, United States
    Recruiting
  • Revival Research Institute, Llc - Troy, Mi
    Troy, Michigan 48084, United States
    Recruiting
  • Medisearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
    Recruiting
  • Boeson Research Mso
    Missoula, Montana 59804, United States
    Recruiting
  • Skin Specialists, Pc
    Omaha, Nebraska 68144, United States
    Recruiting
  • Schweiger Dermatology & Allergy - Verona
    Verona, New Jersey 07044, United States
    Recruiting
  • Vitality Clinical Trials
    Woodbury, New York 11797, United States
    Recruiting
  • Revival Research Institute, Llc - Cary, Nc
    Cary, North Carolina 27511, United States
    Recruiting
  • Darst Dermatology
    Charlotte, North Carolina 28277, United States
    Recruiting
  • Dermatologists Of Southwest Ohio
    Mason, Ohio 45040, United States
    Recruiting
  • Dermatology Associates Of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
    Recruiting
  • Tribe Clinical Research, Llc
    Greenville, South Carolina 29607, United States
    Recruiting
  • Delricht Research - Smyrna
    Smyrna, Tennessee 37167, United States
    Recruiting
  • Dermatology Treatment And Research Center - Dallas
    Dallas, Texas 75230, United States
    Recruiting
  • North Texas Center For Clinical Research
    Frisco, Texas 75034, United States
    Recruiting
  • Austin Institute For Clinical Research Inc.
    Pflugerville, Texas 78660, United States
    Recruiting
  • Texas Dermatology And Laser Specialists
    San Antonio, Texas 78218, United States
    Recruiting
  • Jordan Valley Dermatology
    South Jordan, Utah 84095, United States
    Recruiting
  • Avacare - Cct Research - Springville Dermatology
    Springville, Utah 84663, United States
    Recruiting
  • National Eagle Research, Llc
    Lynnwood, Washington 98036, United States
    Recruiting
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
    Recruiting
  • Dermatology Research Institute (Calgary)
    Calgary, Alberta T2J 7E1, Canada
    Recruiting
  • Alberta Dermasurgery Centre
    Edmonton, Alberta T6G 1C3, Canada
    Recruiting
  • Care Clinic Ltd.
    Red Deer, Alberta T4P 1K4, Canada
    Recruiting
  • Medical Arts Health Research Group - Kelowna
    Kelowna, British Columbia V1Y4N7, Canada
    Recruiting
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
    Recruiting
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
    Recruiting
  • Dr. S. K. Siddha Medicine Professional Corporation
    Newmarket, Ontario L3Y 5G8, Canada
    Recruiting
  • Research Toronto
    Toronto, Ontario M4W 2N4, Canada
    Recruiting
  • Facet Dermatology
    Toronto, M4E 1R7, Canada
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for May 2028, 33 months after the start.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 21, 2025
StartActual
Aug 5, 2025
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07133308
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Aug 5, 2025
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jan 28, 2026

Study contacts

Head Regulatory Affairs
Contact
Clinical.Trial@sunpharma.com
9122 66455645

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion